SFO
MRNA icon

Stokes Family Office’s Moderna MRNA Stock Holding History

Stokes Family Office’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,257
Closed -$226K – 313
2022
Q4 		$226K Buy
+1,257
New +$206K 0.03% 249
2022
Q1 		– Sell
-1,171
Closed -$297K – 272
2021
Q4 		$297K Buy
1,171
+9
+0.8% +$2.63K 0.04% 195
2021
Q3 		$447K Buy
1,162
+88
+8% +$32.5K 0.06% 156
2021
Q2 		$252K Buy
+1,074
New +$192K 0.04% 194

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Stokes Family Office's MRNA Position: Q1 2023 in Review

Stokes Family Office sold out of Moderna (MRNA) in Q1 2023, closing a stake of 1,257 shares — an estimated $226K sold.

Stokes Family Office first reported a position in MRNA in Q2 2021 and held it in 4 quarters. The position peaked at $447K in Q3 2021. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Stokes Family Office reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • Stokes Family Office sold 1,257 Moderna shares in Q1 2023, an estimated $226K.
  • Stokes Family Office first reported a position in Moderna in Q2 2021 and held it in 4 quarters.
  • Stokes Family Office's Moderna position peaked at $447K in Q3 2021.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Stokes Family Office's 13F filing for Q1 2023, filed 8 May 2023.